PEG-3350, Electrolytes, and Ascorbate polyethylene glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid Kit — NDC 68682-201-75 (Billing 68682-0201-75)
This is a package of PEG-3350, Electrolytes, and Ascorbate polyethylene glycol 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid Kit from Oceanside Pharmaceuticals, marketed since Oct 2006 and currently FDA-listed; retail pharmacies pay about $86.81 per unit (NADAC). It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 68682-201-75 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 68682 labeler · 201 product · 75 package
- Package marketed since
- Oct 1, 2006
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6868220175 8
- Medicaid fills, this package
- 1,033 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 061457
- GCN: 97248
- GPI-14 (Medi-Span): 46992006302120
- HICL (First Databank): 034026
- AHFS class code: 56:12.00.00
- RxCUI (RxNorm): 800915
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Vitamin C class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
- No, this is a one-time prescription bowel prep taken only before your colonoscopy. It's not meant for everyday constipation. Its sole job is to flush your colon completely clean so...
- What exactly is this prep for — is it a laxative I'll take regularly?
- Most people have their first bowel movement about 1 to 2 hours after starting the preparation. It will be watery and frequent — that's completely expected and is exactly what the p...
- When will I actually start going to the bathroom after I take it?
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $86.805 | — |
| Medicaid paysCMS SDUD · 12 mo | $74.25 | — |
| Medicare drug plans payPart D · Q2 2026 | $69.15 | — |
Where does this data come from?
- CMS NADAC weekly file · file of Feb 21, 2024
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q4 2025
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 68682-0201-75 You're viewing this Main listing | 1 KIT in 1 CONTAINER * 1 L in 1 POUCH * 1 L in 1 POUCH | 2006-10-01 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Peg-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate And Ascorbic Acid 00093-3560-26 | Teva | 1 kit | $79.534 | AA | Availability likely | save 8% |
| PEG-3350, Electrolytes, and Ascorbatethis 68682-0201-75 | Oceanside | 1 kit | $86.805 | AA | FDA listed | — |
| MoviPrep 65649-0201-75 | Salix | 1 kit | $120.378 | AA | FDA listed | +39% |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Feb 21, 2024
Availability & generic status
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Ascorbic Acid / Polyethylene Glycol 3350 / Potassium Chloride / Sodium Ascorbate / Sodium Chloride / Sodium Sulfate inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Oceanside Pharmaceuticals labeler code 68682
- mesalamine 375 mg Capsule, Extended Release NDC 68682-113-20
- Clindamycin Phosphate and Benzoyl Peroxide 10 mg/g; 25 mg/g Gel NDC 68682-132-50
- Clindamycin Phosphate and Benzoyl Peroxide 10 mg/g; 37.5 mg/g Gel NDC 68682-133-50
- Isosorbide Dinitrate 40 mg Tablet NDC 68682-192-01
- Isosorbide Dinitrate 5 mg Tablet NDC 68682-193-01
- Carbidopa 25 mg Tablet NDC 68682-200-25
- Metronidazole 10 mg/60g Cream NDC 68682-202-60
- Azathioprine 75 mg Tablet NDC 68682-231-01
- Azathioprine 100 mg Tablet NDC 68682-241-01
- Hydrocortisone Butyrate 1 mg/g Ointment NDC 68682-271-15
- Imiquimod 37.5 mg/g Cream NDC 68682-272-75
- Clindamycin Phosphate 1.2% and Tretinoin 0.025% 12 mg/g; .25 mg/g Gel NDC 68682-300-30
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION Preparation and Administration: • Two doses of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution are required for a complete preparation for colonoscopy, using a “Two-Day” preferred method or “One-Day” alternative method dosing regimen. ( 2.1 ) • Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution must be reconstituted in water prior to ingestion. ( 2.1 ) • Additional clear liquids must be consumed after each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in both dosing regimens.
( 2.1 , 5.1 ) • Do not take other laxatives while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. ( 2.1 , 5.5 ) • Do not take oral medications within 1 hour of starting each dose. ( 2.1 ) Dosing Regimen: • Two-Day (Split-Dose) (Preferred Method): Dose 1 the evening before the colonoscopy, and Dose 2 the morning of the colonoscopy (approximately 12 hours after the start of Dose 1, and at least 3 ½ hours prior to the colonoscopy).
( 2.2 ) • One-Day (Evening Only) (Alternative Method) : Dose 1 at least 3 ½ hours prior to bedtime the evening before the colonoscopy and Dose 2 approximately 1 ½ hours after starting Dose 1 the evening before the colonoscopy. ( 2.3 ) • For complete information on dosing, preparation and administration see full prescribing information ( 2.1 , 2.2 , 2.3 )
2.1Important Preparation and Administration Instructions • Correct fluid and electrolyte abnormalities before treatment with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Warnings and Precautions ( 5.1 )]. • Two doses of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution are required for a complete preparation for colonoscopy. The time interval between the two doses depends on the regimen prescribed and the planned timing of the colonoscopy procedure. [see Dosage and Administration ( 2.2 , 2.3 ) ] . • The “Split-Dose” is the preferred method and consists of two separate doses: the first dose is taken the evening before the colonoscopy, and the second dose is taken the next day, the morning of the day of the colonoscopy [see Dosage and Administration ( 2.2 )]. • The “Evening Only” is the alternative method and consists of two separate doses: both doses are taken in the evening before the day of the colonoscopy, with a minimum of 1.5 hours between the start of the first dose and the start of the second dose [see Dosage and Administration ( 2.3 )]. • Both Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution dosing regimens require administration of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution using the mixing container provided to reconstitute the contents of Pouch A and B with water to the Fill Line.
Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container [see Warnings and Precautions ( 5.7 )]. • Additional clear liquids (including water) must be consumed in both dosing regimens [see Dosage and Administration ( 2.2 , 2.3 ), Warnings and Precautions ( 5.1 )] . • Consume only clear liquids (no solid food) from the start of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution treatment until after the colonoscopy. • Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material. • Do not take other laxatives while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Drug Interactions ( 7.3 )] . • Do not take oral medications within 1 hour before or after starting each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Drug Interactions ( 7.2 )]. • Ensure completion of Dose 2, including all additional liquids, at least 2 hours before the colonoscopy. • Storage : After reconstitution, store Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in an upright position… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is supplied as a white to yellow powder for reconstitution and is available in a carton that contains 2 pouches labeled Pouch A and 2 pouches labeled Pouch B. • Each Pouch A contains 100 grams of polyethylene glycol (PEG) 3350, 7.5 grams of sodium sulfate, 2.691 grams of sodium chloride, and 1.015 grams of potassium chloride. Pouch A contains lemon flavoring [see Description ( 11 )] . • Each Pouch B contains 4.7 grams of ascorbic acid and 5.9 grams of sodium ascorbate.
For Oral Solution: 2 pouches labeled Pouch A and 2 pouches labeled Pouch B. ( 3 ) • Each Pouch A contains 100 grams of polyethylene glycol (PEG) 3350, 7.5 grams of sodium sulfate, 2.691 grams of sodium chloride, and 1.015 grams of potassium chloride. Pouch A contains lemon flavoring.
( 3 ) • Each Pouch B contains 4.7 grams of ascorbic acid and 5.9 grams of sodium ascorbate. ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is contraindicated in the following conditions: • Gastrointestinal (GI) obstruction [see Warnings and Precautions ( 5.6 )] • Bowel perforation [see Warnings and Precautions ( 5.6 )] • Gastric retention • Ileus • Toxic colitis or toxic megacolon • Hypersensitivity to any ingredient in Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Warnings and Precautions ( 5.10 ) and Description ( 11 )] • Gastrointestinal (GI) obstruction ( 4 , 5.6 ) • Bowel perforation ( 4 , 5.6 ) • Gastric retention ( 4 ) • Ileus ( 4 ) • Toxic colitis or toxic megacolon ( 4 ) • Hypersensitivity to any ingredient in Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution ( 4 , 5.10 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. ( 5.1 , 7.1 ) • Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. ( 5.2 ) • Seizures : Use caution in patients with a history of seizures and patients at increased risk of seizure, including medications that lower the seizure threshold.
( 5.3 , 7.1 ) • Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing. ( 5.4 , 7.1 , 8.6 ) • Colonic mucosal ulcerations : Consider potential for ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. ( 5.5 ) • Suspected GI obstruction or perforation : Rule out the diagnosis before administration.
( 5.6 ) • Patients at risk for aspiration: Observe during administration. ( 5.7 ) • Glucose-6-phosphate dehydrogenase deficiency (G-6-PD) : Use with caution. ( 5.8 ) • Risks in patients with phenylketonuria : Contains phenylalanine ( 5.9 ) • Hypersensitivity reactions, including anaphylaxis : Inform patients to seek immediate medical care if symptoms occur.
( 5.10 )
5.1Serious Fluid and Electrolyte Abnormalities Advise patients to hydrate adequately before, during, and after the use of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. If a patient develops significant vomiting or signs of dehydration after taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN). Bowel preparations can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment [see Adverse Reactions ( 6.2 )] .
Correct fluid and electrolyte abnormalities before treatment with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)] or in patients with known or suspected hyponatremia. Consider performing pre-dose and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in these patients [see Drug Interactions ( 7.1 )].
5.2Cardiac Arrhythmias There have been rare reports of serious arrhythmias (including atrial fibrillation) associated with the use of ionic osmotic laxative products for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. Use caution when prescribing Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy, or electrolyte imbalance).
Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.
5.3Seizures There have been rare reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.
Use caution when prescribing Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution for patients with a history of seizures and in patients at increased risk of seizure, s… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: • Serious Fluid and Electrolyte Abnormalities [see Warnings and Precautions (5.1) ] • Cardiac Arrhythmias [see Warnings and Precautions (5.2) ] • Seizures [see Warnings and Precautions (5.3)] • Patients with Renal Impairment [see Warnings and Precautions (5.4)] • Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see Warnings and Precautions (5.5)] • Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.6)] • Aspiration [see Warnings and Precautions (5.7)] • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency [see Warnings and Precautions (5.8)] • Risks in Patients with Phenylketonuria [see Warnings and Precautions (5.9)] • Hypersensitivity Reactions [see Warnings and Precautions (5.10) ] Most common adverse reactions (≥ 5%) are: • Two-Day (Split-Dose): malaise, nausea, abdominal pain, vomiting, and upper abdominal pain.
( 6.1 ) • One-Day (Evening-Only): abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution as a Two-Day Split-Dosing and One-Day Evening Only Dosing Regimen was evaluated in two randomized, active-controlled, multicenter, investigator-blinded clinical trials in adult patients scheduled to have an elective colonoscopy [see Clinical Studies (14) ] .
The safety analysis for Study 1 included 359 adult patients ranging in age from 18 to 88 years (mean age 59), with 52% female and 48% male patients. The safety analysis for Study 2 included 340 adult patients ranging in age from 21 to 76 years (mean age 53), with 53% male and 47% female patients. Tables 1 and 2 display adverse reactions reported in at least 2% and 5% of patients in either treatment group in Study 1 and Study 2, respectively.
Since diarrhea was considered as a part of the efficacy assessment, it was not defined as an adverse reaction in these trials. Table 1: Common Adverse Reactions Reported in at least 2% of patients in either treatment group in Patients Undergoing Colonoscopy in Study 1 Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution Two-Day Split Dosing Regimen (N=180) 4 Liter PEG + Electrolytes Solution (N=179) Malaise 19% 18% Nausea 14% 20% Abdominal pain 13% 15% Vomiting 8% 13% Upper abdominal pain 6% 6% Dyspepsia 3% 1% Table 2: Common Adverse Reactions Reported in at least 5% of patients in either treatment group Patients were specifically asked about the occurrence of the following symptoms: shivering, anal irritations, abdominal bloating or fullness, sleep loss, nausea, vomiting, weakness, hunger sensation, abdominal cramps or pain, thirst sensation, and dizziness. in Patients Undergoing Colonoscopy in Study 2 Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution One-Day Evening Only Dosing Regimen (N=169) 90 mL Oral Sodium Phosphate Solution (N=171) Abdominal distension 60% 41% Anal discomfort 51% 52% Thirst 47% 65% Nausea 47% 47% Abdominal pain 39% 32% Sleep disorder 35% 29% Rigors 34% 30% Hunger 30% 71% Malaise 27% 53% Vomiting 7% 8% Dizziness 7% 18% Headache 2% 5% Hypokalemia 0% 6% Hyperphosphatemia 0% 6%
6.2Postmarketing Experience The following adverse reactions have been identified during post-approval use of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution or other PEG-… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Drugs that increase risk for fluid and electrolyte imbalance. ( 7.1 )
7.1Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 , 5.4 )]. Consider additional patient evaluations as appropriate.
7.2Potential for Reduced Drug Absorption Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution can reduce the absorption of other co-administered drugs. Administer oral medications at least 1 hour before the start of administration of each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Dosage and Administration ( 2.1 )] .
7.3Stimulant Laxatives Concurrent use of stimulant laxatives and Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Warnings and Precautions ( 5.5 , 5.6 )].
7.1Drugs That May Increase Risks due to Fluid and Electrolyte Abnormalities Use caution when prescribing Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution for patients with conditions and/or who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 , 5.4 )]. Consider additional patient evaluations as appropriate.
7.2Potential for Reduced Drug Absorption Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution can reduce the absorption of other co-administered drugs. Administer oral medications at least 1 hour before the start of administration of each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution [see Dosage and Administration ( 2.1 )] .
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary There are no available data on Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Animal reproduction studies have not been conducted with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
8.2Lactation Risk Summary There are no data available on the presence of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in human milk, the effects of the drug on the breastfed child, or the effects of the drug on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution and any potential adverse effects on the breastfed child from Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution or from the underlying maternal condition.
8.4Pediatric Use The safety and effectiveness of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in pediatric patients have not been established.
8.5Geriatric Use Of the 413 patients in clinical trials receiving Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, 91 (22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years of age. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other reported clinical experience has not identified differences in responses between geriatric patients and younger patients. However, elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities [see Warnings and Precautions (5.1) ] .
8.6Renal Impairment Use Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function [see Drug Interactions (7.1) ] . These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients [see Warnings and Precautions (5.4)].
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no available data on Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Animal reproduction studies have not been conducted with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Of the 413 patients in clinical trials receiving Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, 91 (22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years of age. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other reported clinical experience has not identified differences in responses between geriatric patients and younger patients. However, elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities [see Warnings and Precautions (5.1) ] .
🆘 Overdosage ▾
10 OVERDOSAGE Overdosage of more than the recommended dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution may lead to severe electrolyte disturbances, including hyponatremia and/or hypokalemia, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances. Certain severe electrolyte disturbances may lead to cardiac arrhythmias, seizures, and renal failure [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . Monitor for fluid and electrolyte disturbances and treat symptomatically.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action The primary mode of action is osmotic action of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.
🧬 Mechanism of Action ▾
12.1Mechanism of Action The primary mode of action is osmotic action of polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution) is supplied as a white to yellow powder for reconstitution and is lemon flavored. NDC 68682-201-75, Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, single-use outer carton: • Each outer carton contains a disposable mixing container with lid for reconstitution of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, prescribing information and patient information, and one inner carton. • Each inner carton contains 2 pouches labeled Pouch A and 2 pouches labeled Pouch B.
Storage Store carton/container at room temperature, between 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). When reconstituted, store upright and keep solution refrigerated. Use within 24 hours [see Dosage and Administration (2.1) ] .
📋 Description ▾
11 DESCRIPTION Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is an osmotic laxative consisting of 4 pouches (2 of Pouch A and 2 of Pouch B) containing white to yellow powder for reconstitution. Each Pouch A contains 100 grams of polyethylene glycol (PEG) 3350, 7.5 grams of sodium sulfate, 2.691 grams of sodium chloride, and 1.015 grams of potassium chloride, plus the following excipients: aspartame (sweetener), acesulfame potassium (sweetener), and lemon flavoring containing citral, lime oil, maltodextrin, acacia gum, vitamin E, and other natural flavoring agents.
Pouch A contains 111.9 g of powder for oral solution. Each Pouch B contains 4.7 grams of ascorbic acid and 5.9 grams of sodium ascorbate. Pouch B contains 10.6 g of powder for oral solution.
When 1 Pouch A and 1 Pouch B are dissolved together in water to a volume of 1 liter, Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is an oral solution having a lemon taste. The entire, reconstituted, 2-liter Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution colon preparation contains 200 grams of polyethylene glycol-3350, 15 grams of sodium sulfate, 5.38 grams of sodium chloride, 2.03 grams of potassium chloride, 9.4 grams of ascorbic acid, and 11.8 grams of sodium ascorbate plus the following excipients: aspartame (sweetener), acesulfame potassium (sweetener), and lemon flavoring.
A mixing container for reconstitution is enclosed. Phenylketonurics: Contains Phenylalanine 131 mg per treatment.
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Instruct patients: • That two doses of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution are required for a complete preparation for colonoscopy either as a Split-Dose (2-Day), or Evening Only (1-Day) dosing regimen [see Instructions for Use] . • Not to take other laxatives while they are taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. • That Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution contains 131 mg of phenylalanine per treatment [see Warnings and Precautions (5.9) ] . • That each pouch needs to be reconstituted in water before ingestion and that they should drink additional clear liquids.
Examples of clear liquids can be found in the Instructions for Use . • Not to take oral medications within one hour of starting each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. • To follow the directions in the Instructions for Use , for either the Two-Day Split-Dosing or the One-Day Evening Only Dosing regimen, as prescribed. • To consume additional clear liquids before, during, and after the use of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution to prevent dehydration [see Warnings and Precautions (5.1) ] . • To contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution or if they experience altered consciousness or seizures [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 , 5.4 )] • Not to eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material. • To stop drinking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution temporarily or drink each portion at longer intervals if they develop severe abdominal discomfort or distention until these symptoms diminish.
If severe symptoms persist, tell patients to contact their healthcare provider. Distributed by: Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA © 2025 Bausch Health Companies Inc. or its affiliates 9676405 70015788-02
💬 Medication Guide ▾
MEDICATION GUIDE POLYETHYLENE GLYCOL-3350, ELECTROLYTES, AND ASCORBATE FOR ORAL SOLUTION (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution) Read this Medication Guide and Instructions for Use before your colonoscopy and again before you start taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. What is the most important information I should know about Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution?
Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution and other bowel preparations can cause serious side effects, including: • Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause: o abnormal heartbeats that can cause death. o seizures. This can happen even if you have never had a seizure. o kidney problems.
Your chance of having fluid loss and changes in body salts with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is higher if you: • have heart problems. • have kidney problems. • take water pills (diuretics), high blood pressure medicine, or non-steroidal anti-inflammatory drugs (NSAIDs). Tell your healthcare provider right away if you have any of these symptoms of serious loss of body fluid (dehydration) while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution: • vomiting • urinating less often than normal • dizziness • headache See “What are the possible side effects of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution?” for more information about side effects .
What is Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution? Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is a prescription medicine used by adults to clean the colon before a colonoscopy. Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution cleans your colon by causing you to have diarrhea (loose stools).
Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy. It is not known if Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is safe and effective in children. Who should not take Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution?
Do not take Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution if your healthcare provider has told you that you have: • a blockage in your intestine (bowel obstruction). • an opening in the wall of your stomach or intestine (bowel perforation). • problems with food and fluid emptying from your stomach (gastric retention). • a problem with food moving too slowly through your intestines (ileus). • a very dilated intestine (toxic megacolon). • an allergy to any of the ingredients in Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution.
See the end of this Medication Guide for a complete list of ingredients in Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. What should I tell my healthcare provider before taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution? Before taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, tell your healthcare provider about all of your medical conditions, including if you: • have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes). • have heart problems. • have seizures or take medicines for seizures. • have kidney problems or take medicines for kidney problems. • have stomach or bowel problems, including ulcerative colitis. • have problems with swallowing, gastric reflux, or if you inhale food or fluid into your lungs when eating or drinking (aspirate). • have a condition called glucose-6-phosphate dehydrogenase (G6PD) deficiency that destroys red blood cells. • are withdrawing from alcohol o… [Excerpted — this section continues on DailyMed.]
🔬 Clinical Studies ▾
14 CLINICAL STUDIES The colon cleansing efficacy and safety of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution was evaluated in two randomized, actively-controlled, multi-center, investigator-blinded trials in adult patients scheduled to have an elective colonoscopy. In Study 1, patients were randomized to one of the following two colon preparation treatments: 1) 2 liters of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution with 1 additional liter of clear liquid split into two doses (during the evening before and the morning of the colonoscopy) and 2) 4 liters of polyethylene glycol plus electrolytes solution (4L PEG + E) split into two doses (during the evening before and the morning of the colonoscopy).
Patients were allowed to have a morning breakfast, a light lunch, clear soup and/or plain yogurt for dinner. Dinner had to be completed at least one hour prior to initiation of the colon preparation administration. The primary efficacy endpoint was the proportion of patients with effective colon cleansing as judged by blinded gastroenterologists on the basis of videotapes recorded during the colonoscopy.
The blinded gastroenterologists graded the colon cleansing twice (during introduction and withdrawal of the colonoscope) and the poorer of the two assessments was used in the primary efficacy analysis. The efficacy analysis included 308 adult patients who had an elective colonoscopy. Patients ranged in age from 18 to 88 years old (mean age about 59 years old) with 52% female and 48% male patients.
Table 3 displays the results. Table 3: Effectiveness of Overall Colon Cleansing of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution vs. 4 Liter Polyethylene Glycol plus Electrolytes Solution in Study 1 Responders A A: colon empty and clean or presence of clear liquid, but easily removed by suction or B C: semisolid amounts of stool, only partially removable with a risk of incomplete visualization of the gut mucosa (%) C D: semisolid or solid amounts of stool; consequently colonoscopy incomplete or needed to be terminated.
(%) D (%) Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution (N=153) 88.9 9.8 1.3 4L PEG + E 4L PEG + E is 4 Liter Polyethylene Glycol plus Electrolytes Solution. (N=155) 94.8 4.5 0.6 4L PEG+E’s responder rate was not significantly higher than Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution’s responder rate. In Study 2, patients were randomized to one of the following two colon preparation treatments: 1) 2 liters of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution with 1 additional liter of clear liquid in the evening prior to the colonoscopy and 2) 90 mL of oral sodium phosphate solution (90 mL OSPS) with at least 2 liters of additional clear liquid during the day and evening prior to the colonoscopy.
Patients randomized to Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution therapy were allowed to have a morning breakfast; a light lunch; and clear soup and/or plain yogurt for dinner. Dinner had to be completed at least one hour prior to initiation of the colon preparation administration. The primary efficacy endpoint was the proportion of patients with effective colon cleansing as judged by the colonoscopist and one blinded gastroenterologist (on the basis of videotapes recorded during the colonoscopy).
In case of a discrepancy between the colonoscopist and the blinded gastroenterologist, a second blinded gastroenterologist made the final efficacy determination. The efficacy analysis included 280 adult patients who had an elective colonoscopy. Patients ranged in age from 21 to 76 years old (mean age about 53 years old) with 47% female and 53% male patients.
Table 4 displays the results. Table 4: Effectiveness of Overall Colon Cleansing of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution vs. 90 mL Oral Sodium Phosphate Solution in Study… [Excerpted — this section continues on DailyMed.]
📖 Instructions for Use ▾
Instructions for Use POLYETHYLENE GLYCOL-3350, Electrolytes, and Ascorbate for Oral Solution (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution) There are two different options for taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. Your healthcare provider will tell you to take the Two-Day Split-Dosing Regimen option or the One-Day Evening Only Dosing Regimen option. Important Information on Polyethylene Glyco l -3350, Electrolytes, and Ascorbate for Oral Solution: • You must drink all of the Dose 1 and Dose 2 of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution with either dosing regimen option.
Make sure you finish Dose 2 at least 2 hours before your colonoscopy. • After completing Dose 2, it is important that you drink additional clear liquids (including water), but you must stop drinking all liquids at least 2 hours before your colonoscopy. • Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution is lemon flavored containing citral, lime oil, maltodextrin, acacia gum, vitamin E, and other natural flavoring agents. • Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution must be mixed with water.
Do not add any other ingredients to Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. • Do not mix Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution with starch-based thickeners. • After you start taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, you can only drink clear liquids (no solid foods) until after your colonoscopy. Examples of clear liquids include: o water o clear fruit juices without pulp including apple, white grape, or white cranberry o strained limeade or lemonade o coffee or tea ( do not use any dairy or non-dairy creamer) o clear broth o clear soda o gelatin (without added fruit or topping, no red or purple) o popsicles (without pieces of fruit or pulp, no red or purple) • Drink plenty of clear liquids before, during, and after you take Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, up until 2 hours before your colonoscopy, to help prevent fluid loss (dehydration). • Do not eat or drink anything within 2 hours before your colonoscopy. • Do not eat or drink alcohol, milk, anything colored red or purple or containing pulp. • Do not take other laxatives while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. • Do not take any medicines by mouth (oral) within 1 hour before or after starting each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. • Do not eat any solid food while taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution until after your colonoscopy.
To take each dose of Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution, you will need: o Mixing Container that comes with Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution o One Pouch A o One Pouch B o Lukewarm water • For the Two-Day Split-Dosing Regimen: o On the day before the colonoscopy you can eat breakfast followed by a light lunch (no solid foods). For dinner you may have a clear soup with or without plain yogurt, or plain yogurt only. o You must finish eating at least 1 hour before you start taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution. o You must take the first dose between 10 to 12 hours before the second dose.
The second dose must be taken at least 3 ½ hours before the colonoscopy. o After you start taking Polyethylene Glycol-3350, Electrolytes, and Ascorbate for Oral Solution you can only drink clear liquids. • For the One-Day Evening Only Dosing Regimen: o On the day before the colonoscopy you can eat breakfast followed by a light lunch. For dinner you may have a clear soup with or without plain yogurt, or plain yogurt only.… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL PRINCIPAL DISPLAY PANEL - POLYETHYLENE GLYCOL-3350, Electrolytes, and Ascorbate for Oral Solution Outer Carton Rx only NDC 68682-201-75 POLYETHYLENE GLYCOL-3350, ELECTROLYTES, AND ASCORBATE FOR ORAL SOLUTION (Polyethylene Glycol-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution) 100 g/7.5 g/2.691 g/1.015 g/5.9 g/4.7 g OCEANSIDE Pharmaceuticals 9676304 70016299-02 carton
Medicaid utilization & spend
About this NDC listing & data coverage
Kit / multi-component package
This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | ✓ Available |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |